CoLucid Hopes Lasmiditan Can Offer New, Safer Migraine Drug Class
Prospects that CoLucid Pharmaceuticals’ lead asset might offer a viable new class of migraine treatment are brighter following the release of positive Phase III data showing lasmiditan helps twice as many patients to be headache-free after two hours versus a placebo.
You may also be interested in...
Lilly's Lasmiditan NDA Review Could Hinge On US FDA's Migraine Guidance
Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva.
Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy
Lilly will submit lasmiditan for FDA approval after a second positive Phase III study, giving the company a product to stop migraine when its galcanezumab isn't able to prevent the headaches.
Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m
In acquiring biotech CoLucid and its Phase III acute migraine candidate lasmiditan for $960m, Lilly gets back an asset it discovered and out-licensed more than a decade ago. The pharma hopes to pair the 5-HT1F agonist with galcanezumab to create a two-drug migraine franchise.